Loading...
NPI 1699162966 · Las Vegas, NV · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Sl Consulting LLC is a clinical medical laboratory provider located in Las Vegas, Nevada. This profile covers 70 Medicare and 79 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Sl Consulting LLC |
| Address | 8445 S Eastern Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89123 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 23, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $11.6M |
| Medicare | $1.7M |
SL CONSULTING LLC’s claim mix and highest-value CPT/HCPCS suggest it operates primarily as a high-throughput clinical diagnostic laboratory focused on molecular infectious disease testing and definitive drug panels. Medicare billing is led by COVID molecular testing and comprehensive drug testing codes — notably U0004 (6.3K claims, $468.9K revenue, 28.0%), G0483 (1.6K claims, $394.2K revenue, 23.5%), and 87798 (6.2K claims, $211.2K revenue, 12.6%) — and the presence of U0005, U0002, and multiplex respiratory codes (e.g., 87631) reinforces a heavy emphasis on nucleic-acid amplification testing workflows.
Revenue concentration is high on both payers: the top 3 Medicare codes by revenue account for 64.2% of the provider’s Medicare revenue, driven by U0004, G0483, and 87798. That concentration indicates a reliance on a small set of high-volume molecular and definitive drug-testing services for the Medicare line of business.
Medicaid billing shows an even stronger concentration in a similar service mix: the top 3 Medicaid codes by revenue account for 70.6% of the provider’s Medicaid revenue, with G0483 (50.5K claims, $3.4M revenue, 29.3%), 87798 (19.5K claims, $3M revenue, 25.8%), and U0004 (47K claims, $1.8M revenue, 15.5%) as the dominant drivers. This pattern implies the provider’s Medicaid business is likewise concentrated in high-volume drug testing and COVID/NAAT services.
Payer mix is skewed dramatically toward Medicaid in scale: total Medicare revenue is $1.7M while total Medicaid revenue is $11.6M, so Medicaid represents the lion’s share of reported public-payer volume. Practically, SL CONSULTING LLC functions as a Medicaid-focused laboratory in terms of revenue scale, with Medicare present but proportionally much smaller.
Against peers, the provider is a major statewide Medicaid player and an above-typical national participant on several Medicare codes. For Medicaid, G0483 ranks #2 of 41 in-state (98th percentile; notably above typical state volume) and 87798 ranks #2 of 27 in-state (96th percentile; notably above typical state volume); for Medicare, U0004 ranks #14 of 259 nationally (95th percentile; notably above typical national volume) and G0483 ranks #65 of 1063 nationally (94th percentile). These rank/percentile positions indicate local market dominance for several test types and above-average national presence on key COVID testing codes.
Several listings are flagged as statistical outliers in-state, implying exceptional throughput on specific assays: Medicaid 87631 ranks #1 of 24 in-state (100th percentile; extreme outlier, far above typical state volume), and multiple NAAT codes (e.g., 87486, 87581, 87541, 87532, 87496) rank #1 in-state at the 100th percentile. Combined with high claim counts for G0483 and 80307 in Medicaid, this suggests centralized, high-volume sample processing and specialized capacity for both definitive drug testing and nucleic-acid amplified pathogen testing.
Operational history and business risk: the NPI was enumerated 2015-04-23 (~11 years ago), indicating an established billing presence. However, the business is concentrated by payer (Medicaid-heavy) and by a small set of codes (top 3 = 64.2% Medicare, top 3 = 70.6% Medicaid), which creates revenue sensitivity to payer policy or reimbursement changes affecting high-volume molecular and drug-testing codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
70 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 6,340 | $70 | $468.9K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,630 | $240 | $394.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6,210 | $30 | $211.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 6,330 | $30 | $158.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,580 | $60 | $96.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 450 | $200 | $88.5K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 390 | $140 | $54.6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 650 | $50 | $32.5K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 2,990 | $10 | $17.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 140 | $110 | $15.9K |
Showing 1–10 of 70
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 70 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
79 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50,480 | $70 | $3.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 19,540 | $150 | $3M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 47,030 | $40 | $1.8M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 57,790 | $20 | $1.3M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,510 | $30 | $262.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 11,360 | $20 | $227.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 11,300 | $20 | $214.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,030 | $40 | $127K |
| 87511 | The lab analyst performs a test for Gardnerella vaginalis using amplified nucleic acid probe technique. Gardnerella vaginalis, typically causes bacterial vaginosis, an infection of the vagina that… | 4,070 | $30 | $118K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 4,310 | $30 | $116.3K |
Showing 1–10 of 79
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
79 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 10 | 2,010 | $50 | $677.8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 40 | 530 | $70 | $561K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2 | 30 | 290 | $60 | $260.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 30 | 750 | $90 | $252.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6 | 150 | 1,440 | $20 | $193.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 50 | 910 | $40 | $164K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 40 | 310 | $50 | $129.2K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 9 | 40 | 130 | $10 | $89.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 37 | 130 | 1,600 | $1 | $74.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 11 | 90 | 250 | $10 | $64.7K |
Showing 1–10 of 79
Other providers in the same ZIP code as Sl Consulting LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.